Buy OSI Pharmaceuticals (OSIP) on Weakness -Piper Jaffray
More News related to OSIP
- Biotech Takeover Buzz Hot and Heavy After ImClone Offer (ONXX, OSIP, BIIB, AMLN, XPNT, CYPB, ISPH)
- Piper Jaffray Increases Their Price Target on OSI Pharmaceuticals (OSIP) to $58
- OSI Pharmaceuticals (OSIP) Reports Q2 EPS of $0.61, Beats by 9c
- OSI Pharmaceuticals Announces Second Quarter 2008 Financial Results
- OSI Pharmaceuticals (OSIP) Initiates Phase I Trial for OSI-027 in Patients with Lymphoma
More News related to Analyst Comments
- ARGUS Maintains Hold Rating on Wyeth (WYE)
- Dell (DELL): Colour on quarter
- Deutsche Bank Cuts Price Target on Sigma Designs (SIGM) to $25; Maintains Buy
- Citi Reiterates 'Buy' Rating on Marvell Technology (MRVL)
- Affymax (AFFY) "Significantly Undervalued"; Buy on Weakness -Baird
Piper Jaffray reiterates its Buy rating and $50 price target on OSI Pharmaceuticals (Nasdaq: OSIP).
The firm mentions that OSI has a hearing scheduled next week in regards to license issues for Tarceva and Piper Jaffray believes that the license is unlikely to be granted. With the stock down almost 6% today, and about 23% year-to-date, Piper Jaffray said it would be a buyer of the OSI stock on current weakness.
OSI Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of oncology, diabetes, and obesity in the United States.
Related Categories
Analyst CommentsStocks Mentioned
-0.13Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
